Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
76.32
+2.66 (3.61%)
Nov 25, 2025, 4:00 PM EST - Market closed
Revolution Medicines Employees
Revolution Medicines had 534 employees as of December 31, 2024. The number of employees increased by 156 or 41.27% compared to the previous year.
Employees
534
Change (1Y)
156
Growth (1Y)
41.27%
Revenue / Employee
n/a
Profits / Employee
-$1,799,584
Market Cap
14.75B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | 125 | 30 | 31.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RVMD News
- 7 days ago - Revolution Medicines, Inc. (RVMD) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 14 days ago - Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 20 days ago - Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 21 days ago - Revolution Medicines to Participate in November 2025 Investor Conferences - GlobeNewsWire
- 27 days ago - Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 - GlobeNewsWire
- 4 weeks ago - Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor - GlobeNewsWire